Lytix Biopharma AS Asset Resilience Ratio
Lytix Biopharma AS asset resilience ratio. Lytix Biopharma AS (LYTIX) has an Asset Resilience Ratio of 88.76% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See LYTIX defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Lytix Biopharma AS (2017–2025)
Asset resilience ratio of Lytix Biopharma AS from 2017 to 2025. This chart shows how Lytix Biopharma AS's Asset Resilience Ratio has changed over time. Read Lytix Biopharma AS balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Lytix Biopharma AS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Lytix Biopharma AS.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr10.60 Million | 13.0% |
| Short-term Investments | Nkr61.76 Million | 75.75% |
| Total Liquid Assets | Nkr72.36 Million | 88.76% |
Asset Resilience Insights
- Very High Liquidity: Lytix Biopharma AS maintains exceptional liquid asset reserves at 88.76% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Lytix Biopharma AS Industry Peers by Asset Resilience Ratio
Compare Lytix Biopharma AS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Lytix Biopharma AS Asset Resilience Ratio by Year (2017–2025)
Lytix Biopharma AS asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Lytix Biopharma AS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 88.76% | Nkr72.36 Million ≈ $7.61 Million |
Nkr81.52 Million ≈ $8.58 Million |
-0.50pp |
| 2024-12-31 | 89.26% | Nkr130.79 Million ≈ $13.76 Million |
Nkr146.53 Million ≈ $15.42 Million |
+10.12pp |
| 2023-12-31 | 79.14% | Nkr50.55 Million ≈ $5.32 Million |
Nkr63.87 Million ≈ $6.72 Million |
-16.35pp |
| 2022-12-31 | 95.49% | Nkr145.16 Million ≈ $15.27 Million |
Nkr152.02 Million ≈ $16.00 Million |
-1.71pp |
| 2021-12-31 | 97.20% | Nkr197.28 Million ≈ $20.76 Million |
Nkr202.96 Million ≈ $21.36 Million |
+9.98pp |
| 2020-12-31 | 87.22% | Nkr28.45 Million ≈ $2.99 Million |
Nkr32.62 Million ≈ $3.43 Million |
+13.83pp |
| 2019-12-31 | 73.40% | Nkr12.80 Million ≈ $1.35 Million |
Nkr17.43 Million ≈ $1.83 Million |
-10.85pp |
| 2018-12-31 | 84.25% | Nkr49.62 Million ≈ $5.22 Million |
Nkr58.90 Million ≈ $6.20 Million |
+10.01pp |
| 2017-12-31 | 74.23% | Nkr34.96 Million ≈ $3.68 Million |
Nkr47.09 Million ≈ $4.96 Million |
-- |
About Lytix Biopharma AS
Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic… Read more